Seres Therapeutics, Inc. (MCRB)
MCRB moved a median of -0.23% 30 minutes after news, and -0.70% by the close. How MCRB actually reacts to news — the realized, point-in-time move the market made, measured across 290 labeled events over the last three years with zero look-ahead.
MCRB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 284 |
| 30-min | -0.23% | 46% | 290 |
| 60-min | -0.01% | 46% | 290 |
| to close | -0.70% | 47% | 290 |
| Middle 50% of MCRB reactions | -2.98% to +1.91% |
|---|---|
| Median reaction (30-min) | -0.23% |
| Measured reactions | 290 |
Half of all Seres Therapeutics, Inc. news events land between -2.98% and +1.91% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MCRB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +2.79% | 70% | +2.25% |
| Analyst downgrades | 16 | -0.40% | 44% | -5.61% |
| Rating reiterations | 25 | -1.52% | 24% | 0.00% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how MCRB ranks against every other measured name →
That’s how MCRB usually reacts — get an email when it moves on news →Email me when MCRB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MCRB's baseline. Nothing else.
Recent MCRB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | — | — | |
| Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +1.00% | +3.60% | |
| Form EFFECT Seres Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.11% | +3.33% | |
| Form S-3 Seres Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.22% | +0.67% | |
| Form 10-Q Seres Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.48% | -0.69% | |
| Form 8-K Seres Therapeutics, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -1.95% | -11.10% | |
| Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs | Press release | GlobeNewswire | -1.95% | -11.10% | |
| Form 8-K Seres Therapeutics, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -1.95% | -11.10% | |
| Form S-8 Seres Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -1.93% | -9.21% | |
| Form 8-K Seres Therapeutics, Inc. For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | -9.73% | |
| Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment | Press release | GlobeNewswire | +0.19% | -9.73% | |
| Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis | Press release | GlobeNewswire | +2.87% | +0.66% | |
| Form 8-K Seres Therapeutics, Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -6.79% | -15.00% | |
| Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 | Press release | GlobeNewswire | -6.79% | -15.00% | |
| Form 8-K Seres Therapeutics, Inc. For: May 30 | SEC filing · Form 8-K | SEC EDGAR | -1.57% | -3.81% | |
| Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference | Press release | GlobeNewswire | -0.64% | +1.66% | |
| Form 10-Q Seres Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.72% | -1.05% | |
| Form 8-K Seres Therapeutics, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +2.93% | -0.13% | |
| Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +2.93% | -0.13% | |
| Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease | Press release | GlobeNewswire | +0.92% | +0.79% | |
| Form DEF 14A Seres Therapeutics, Inc. For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | +3.89% | -4.83% | |
| Form DEFA14A Seres Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +3.89% | -4.83% | |
| Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 | Press release | GlobeNewswire | -2.38% | +1.48% | |
| Seres Therapeutics to Present at CARB-X Investor Day | Press release | GlobeNewswire | +0.00% | -0.68% | |
| Form 8-K Seres Therapeutics, Inc. For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | -0.22% | +4.28% | |
| Form 10-K Seres Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | +1.34% | |
| Form 8-K Seres Therapeutics, Inc. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.56% | |
| Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +0.00% | +0.56% | |
| Form 8-K Seres Therapeutics, Inc. For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | +1.03% | |
| Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates | Press release | GlobeNewswire | +1.51% | +1.03% | |
| Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases | Press release | GlobeNewswire | -1.39% | -18.13% | |
| Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy | Press release | GlobeNewswire | +0.00% | +3.60% | |
| Seres Therapeutics to Participate in Piper Sandler Healthcare Conference | Press release | GlobeNewswire | -0.51% | -3.85% | |
| Form 10-Q Seres Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.46% | -2.46% | |
| Form 8-K Seres Therapeutics, Inc. For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +1.46% | -7.30% | |
| Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +1.46% | -7.30% | |
| Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 | Press release | GlobeNewswire | +0.00% | -5.45% | |
| Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 | Press release | GlobeNewswire | -1.60% | -0.06% | |
| Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant | Press release | GlobeNewswire | -0.47% | +1.28% | |
| Form 8-K Seres Therapeutics, Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -0.98% | +2.44% | |
| Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway | Press release | GlobeNewswire | +0.55% | +7.01% | |
| Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | +1.10% | -0.63% | |
| Form 10-Q Seres Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.95% | -6.29% | |
| Form 8-K Seres Therapeutics, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.74% | -2.58% | |
| Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +0.74% | -2.58% | |
| Form 8-K Seres Therapeutics, Inc. For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | -3.69% | +0.69% | |
| Seres Therapeutics Announces Leadership Transition | Press release | GlobeNewswire | -9.75% | -9.16% | |
| Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 | Press release | GlobeNewswire | -9.75% | -9.16% | |
| Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting | Press release | GlobeNewswire | -2.95% | -7.19% | |
| Form 10-Q Seres Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.49% | -2.93% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MCRB section they belong to.
Where else MCRB is measured.
MCRB earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Merus N.V. - Common Shares (MRUS) | 292 | +0.03% | 54% |
| CRISPR Therapeutics AG - Common Shares (CRSP) | 291 | +0.10% | 53% |
| Adicet Bio, Inc. (ACET) | 288 | -0.80% | 36% |
| Xencor, Inc. (XNCR) | 288 | +0.09% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Seres Therapeutics, Inc.'s median reaction calculated?
Every labeled MCRB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 290 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of MCRB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does MCRB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.